These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35767735)

  • 1. The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.
    Tabanelli V; Melle F; Motta G; Mazzara S; Fabbri M; Agostinelli C; Calleri A; Del Corvo M; Fiori S; Lorenzini D; Cesano A; Chiappella A; Vitolo U; Derenzini E; Griffin GK; Rodig SJ; Vanazzi A; Sabattini E; Tarella C; Sapienza MR; Pileri SA
    Blood Adv; 2022 Aug; 6(15):4634-4644. PubMed ID: 35767735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
    Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
    Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.
    Kim YS; Ji JH; Ko YH; Kim SJ; Kim WS
    Acta Haematol; 2014; 131(3):156-61. PubMed ID: 24192382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotypic Characterization and Purification of Neoplastic Cells from Lymph Nodes Involved by T-Cell/Histiocyte-rich Large B-cell Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting.
    Glynn E; Fromm JR
    Cytometry B Clin Cytom; 2020 Jan; 98(1):88-98. PubMed ID: 31254446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial phenotyping of nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma.
    Younes S; Subramanian A; Khan A; Zhao S; Binkley M; Natkunam Y
    Blood Cancer J; 2024 May; 14(1):92. PubMed ID: 38821935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma.
    Hartmann S; Döring C; Vucic E; Chan FC; Ennishi D; Tousseyn T; de Wolf-Peeters C; Perner S; Wlodarska I; Steidl C; Gascoyne RD; Hansmann ML
    Br J Haematol; 2015 May; 169(3):415-22. PubMed ID: 25644177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype.
    Hartmann S; Tousseyn T; Döring C; Flüchter P; Hackstein H; Herreman A; Ponzoni M; de Wolf-Peeters C; Facchetti F; Gascoyne RD; Küppers R; Steidl C; Hansmann ML
    Int J Cancer; 2013 Dec; 133(11):2609-18. PubMed ID: 23686423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
    Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
    APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
    Zhang J; Guo Y; Fang H; Guo X; Zhao L
    Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade and CAR T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma: Challenges and opportunities.
    Sahin TK; Akin S
    Heliyon; 2024 Sep; 10(18):e38023. PubMed ID: 39328551
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
    Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
    Griffin GK; Weirather JL; Roemer MGM; Lipschitz M; Kelley A; Chen PH; Gusenleitner D; Jeter E; Pak C; Gjini E; Chapuy B; Rosenthal MH; Xu J; Chen BJ; Sohani AR; Lovitch SB; Abramson JS; Ishizuka JJ; Kim AI; Jacobson CA; LaCasce AS; Fletcher CD; Neuberg D; Freeman GJ; Hodi FS; Wright K; Ligon AH; Jacobsen ED; Armand P; Shipp MA; Rodig SJ
    Blood; 2021 Mar; 137(10):1353-1364. PubMed ID: 32871584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
    Wada F; Kamijo K; Shimomura Y; Yamashita D; Hara S; Ishikawa T
    Immunology; 2024 Feb; 171(2):224-234. PubMed ID: 37904615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.
    Ollila TA; Reagan JL; Olszewski AJ
    Leuk Lymphoma; 2019 Dec; 60(14):3426-3433. PubMed ID: 31287335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification.
    Tousseyn T; De Wolf-Peeters C
    Virchows Arch; 2011 Dec; 459(6):557-63. PubMed ID: 22081105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.